Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial-Onset Seizures Age: Adults and adolescents greater than 16 years Condition: Adjunctive therapy in treating partial-onset seizures with or without secondary generalization in patients with epilepsy |
Dose: Monotherapy or adjunctive therapy – 50 mg Frequency: twice daily (100 mg per day) Note: Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day) |
|
Indication: Partial-Onset Seizures Age: Adults and adolescents greater than 16 years Condition: Patients when oral administration is temporarily not feasible |
Dose: Injection – Dosage based on oral regimen Note: Clinical study experience with injection is limited to 4 consecutive days of treatment |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial Onset Seizures Age: Child (16 years and older) |
Dose: Tablet, oral solution, or Injection – 50 mg Frequency: twice daily Note: Initial dose (100 mg per day) |
|
Indication: Partial Onset Seizures Age: Child (16 years and older) |
Dose: Tablet, oral solution, or Injection – 25 mg to 100 mg Frequency: twice daily Note: Minimum and maximum maintenance dose (50 mg to 200 mg per day) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate renal impairment |
Dose: Not specified Note: No dose adjustment required |
|
Condition: End-stage renal disease undergoing dialysis |
Dose: Not specified Note: Not studied |
Administration
- Take with or without food
- Take at same time each day
Side Effect
- Somnolence and sedation (16%)
- Dizziness (12%)
- Fatigue (9%)
- Nausea and vomiting (5%)
- Cerebellar coordination and balance disturbances (3%)
- Irritability (3%)
- Constipation (2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP2C19 inhibitors (e.g. fluconazole, fluvoxamine)
|
Possible increase in plasma concentration
|
|
Strong enzyme inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, St. John's wort)
|
Decreased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
History of bronchospasm
|
Risk of breathing difficulties
|
|
History of angioedema
|
Risk of severe swelling
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25°C; excursions permitted between 15°C to 30°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.